axitinib,sunitinib,pembrolizumab
pfizer,merck
['sunitinib', 'axi+', 'kn-42', 'pembro', 'rcc,(-irccs),(-srcc),(-urcc)', 'kn-426']
 5-yr f/u of kn-426 of #1l axi+pembro maintains pfs, os, orr (11% cr w/combo) superiority over sunitinib in adv #ccrcc irrespective of imdc risk. 28% completed 2 yrs of pembro (85% orr, os nr, median pfs 37.4 mos in those who make it to 35 cycles) #asco23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope